Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNA NASDAQ:CSBR NASDAQ:NBTX NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNAAleAnna$4.87+8.5%$6.52$4.32▼$18.70$324.59M0.0219,359 shs1,316 shsCSBRChampions Oncology$6.47-33.1%$10.15$3.60▼$11.99$90.24M0.4640,472 shs32,633 shsNBTXNanobiotix$7.40+2.9%$5.30$2.76▼$7.74$348.53M0.4511,191 shs6,558 shsTNXPTonix Pharmaceuticals$46.46-1.0%$39.63$6.76▼$130.00$341.81M1.71.31 million shs670,373 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNAAleAnna-5.07%-11.79%-16.07%-58.92%+448,999,900.00%CSBRChampions Oncology-4.80%-3.90%-26.81%+1.90%+36.78%NBTXNanobiotix+4.81%+4.20%+32.41%+110.85%+53.63%TNXPTonix Pharmaceuticals+2.85%+24.52%+31.95%+149.04%+2.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNAAleAnnaN/AN/AN/AN/AN/AN/AN/AN/ACSBRChampions Oncology3.8591 of 5 stars3.54.00.04.40.02.51.3NBTXNanobiotix0.3318 of 5 stars1.33.00.00.00.00.00.6TNXPTonix Pharmaceuticals3.2075 of 5 stars3.53.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNAAleAnna 0.00N/AN/AN/ACSBRChampions Oncology 3.00Buy$12.0085.59% UpsideNBTXNanobiotix 2.50Moderate Buy$8.008.18% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.0050.67% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, NBTX, ANNA, and TNXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNAAleAnna$1.42M228.58N/AN/A$0.75 per share6.49CSBRChampions Oncology$56.94M1.56$0.45 per share14.28$0.27 per share23.95NBTXNanobiotix$39.18M8.90N/AN/A($1.51) per share-4.90TNXPTonix Pharmaceuticals$10.04M34.04N/AN/A$31.82 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNAAleAnna-$12.34M-$0.02N/A∞N/AN/A-57.32%-26.71%N/ACSBRChampions Oncology$4.70M-$0.0619.23∞N/A8.26%196.12%16.62%N/ANBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest CSBR, NBTX, ANNA, and TNXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q1 2025TNXPTonix Pharmaceuticals-$6.71N/AN/AN/A$2.60 millionN/A7/23/2025Q4 2025CSBRChampions OncologyN/A-$0.13N/A-$0.13N/A$12.35 million5/15/2025Q1 2025ANNAAleAnnaN/A-$0.05N/A-$0.05N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNAAleAnnaN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNAAleAnna0.0313.5513.55CSBRChampions OncologyN/A0.940.94NBTXNanobiotixN/A1.041.04TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNAAleAnna38.10%CSBRChampions Oncology41.30%NBTXNanobiotix38.81%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipANNAAleAnna42.90%CSBRChampions Oncology46.98%NBTXNanobiotix3.45%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNAAleAnnaN/A66.65 million38.06 millionN/ACSBRChampions Oncology14313.78 million7.31 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableCSBR, NBTX, ANNA, and TNXP HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (TNXP) Expected to Announce Earnings on FridayAugust 8 at 2:15 AM | marketbeat.comWhat is Zacks Small Cap's Estimate for TNXP Q2 Earnings?August 1, 2025 | marketbeat.comZacks Small Cap Has Bullish Forecast for TNXP Q2 EarningsAugust 1, 2025 | americanbankingnews.comTNXP: 2Q25 Financial Update and Deep Dive Into TNX-1500…July 29, 2025 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedJuly 29, 2025 | marketbeat.comIFP Advisors Inc Makes New Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)July 29, 2025 | marketbeat.comTonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by FibromyalgiaJuly 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?July 19, 2025 | marketbeat.comTonix Pharma Plans Sales Force for TNX-102 SLJuly 16, 2025 | tipranks.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.8% - Time to Sell?July 11, 2025 | marketbeat.comTonix up after peer reviewed data for pain therapy and new data for mpox vaccineJuly 10, 2025 | msn.comTonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine ResultsJuly 10, 2025 | msn.comTonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data ReleaseJuly 10, 2025 | gurufocus.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?July 10, 2025 | marketbeat.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock NewsJuly 10, 2025 | gurufocus.comTonix Pharma Unveils Promising TNX-801 Vaccine FindingsJuly 10, 2025 | tipranks.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025July 10, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's WhyJuly 9, 2025 | marketbeat.comTonix Pharma Publishes Phase 3 Trial ResultsJuly 9, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?Tilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?CSBR, NBTX, ANNA, and TNXP Company DescriptionsAleAnna NASDAQ:ANNA$4.87 +0.38 (+8.46%) As of 03:13 PM EasternAleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy's natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Nanobiotix NASDAQ:NBTX$7.40 +0.21 (+2.85%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Tonix Pharmaceuticals NASDAQ:TNXP$46.46 -0.46 (-0.98%) Closing price 03:59 PM EasternExtended Trading$46.22 -0.24 (-0.52%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
